{
    "clinical_study": {
        "@rank": "58657", 
        "acronym": "SALT", 
        "arm_group": {
            "arm_group_label": "MS patients", 
            "description": "MS patients"
        }, 
        "biospec_descr": {
            "textblock": "Blood, urine"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Recently, it has been shown that salt (ClNa, sodium chloride) can modulate the\n      differentiation of human and mouse TH17 cells. Indeed, mice feed with high sodium diet were\n      described to develop more aggressive course of EAE (Experimental Autoimmune Encephalitis).\n\n      However, the role of sodium intake in MS has not been investigated. In this study we\n      investigate the effect of sodium intake in Multiple Sclerosis (MS) clinical and radiological\n      activity."
        }, 
        "brief_title": "Sodium Intake in Multiple Sclerosis", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is between 18 and 50 years old\n\n          -  Subject has diagnosis of relapsing-remitting MS according to McDonald criteria (2010)\n\n        Exclusion Criteria:\n\n          -  Patient who had hyponatremia in the last 90 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "A total of 70 patients with relapsing-remitting MS according to McDonald criteria1 were\n        recruited from the MS clinic at FLENI by attending neurologists. A second group of 52\n        relapsing-remitting MS patients was recluted later."
            }
        }, 
        "enrollment": {
            "#text": "132", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01846234", 
            "org_study_id": "Salt", 
            "secondary_id": "Salt-1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Sclerosis", 
            "Salt"
        ], 
        "lastchanged_date": "October 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Buenos Aires", 
                    "country": "Argentina", 
                    "zip": "1428"
                }, 
                "name": "FLENI"
            }
        }, 
        "location_countries": {
            "country": "Argentina"
        }, 
        "number_of_groups": "1", 
        "official_title": "Effect of Sodium Intake in Multiple Sclerosis Disease Activity", 
        "overall_official": {
            "affiliation": "Fundaci\u00f3n para la Lucha contra las Enfermedades Neurol\u00f3gicas de la Infancia", 
            "last_name": "Mauricio F Farez, MD MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Argentina: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of disease relapses during follow up time according to salt consumption", 
            "measure": "Exacerbation rate", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01846234"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fundaci\u00f3n para la Lucha contra las Enfermedades Neurol\u00f3gicas de la Infancia", 
            "investigator_full_name": "Mauricio F. Farez", 
            "investigator_title": "Research Associate", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Number of new lesions in MRI", 
            "measure": "Radiological activity", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "source": "Fundaci\u00f3n para la Lucha contra las Enfermedades Neurol\u00f3gicas de la Infancia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n para la Lucha contra las Enfermedades Neurol\u00f3gicas de la Infancia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}